tenofovir has been researched along with rilpivirine in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (2.90) | 29.6817 |
| 2010's | 57 (82.61) | 24.3611 |
| 2020's | 10 (14.49) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Susman, E | 1 |
| Debyser, Z; Desimmie, BA; Schrijvers, R | 1 |
| Andrade-Villanueva, J; Boven, K; Clotet, B; Cohen, CJ; Crauwels, H; Fourie, J; Johnson, MA; Rimsky, LT; Ruxrungtham, K; Vanveggel, S; Wu, H; Zorrilla, C | 1 |
| Boven, K; Cahn, P; Crauwels, H; Grinsztejn, B; Lazzarin, A; Mills, A; Molina, JM; Rimsky, LT; Saag, M; Supparatpinyo, K; Vanveggel, S; Walmsley, S | 1 |
| Arasteh, K; Boven, K; Crauwels, H; De Wet, J; Gathe, J; Gold, J; Hodder, S; Kumar, P; Mohapi, L; Short, W; Vanveggel, S | 1 |
| De Clercq, E | 1 |
| Calvez, V; Flandre, P; Fofana, DB; Fourati, S; Katlama, C; Lambert, S; Malet, I; Marcelin, AG; Sayon, S; Simon, A; Soulie, C; Wirden, M | 1 |
| Lyseng-Williamson, KA; Scott, LJ | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Fofana, DB; Fourati, S; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Soulié, C; Storto, A; Visseaux, B; Wirden, M | 1 |
| Aldir, I; Horta, A; Serrado, M | 1 |
| Cheng, A; Custodio, JM; Hepner, M; Kearney, BP; Ling, KH; Ramanathan, S; Yin, X | 1 |
| Estrada, V; Portilla, J | 1 |
| Feng, JY; Kulkarni, R; Miller, MD; White, KL | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Flandre, P; Fofana, D; Fourati, S; Lambert-Niclot, S; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Soulie, C; Storto, A; Wirden, M | 1 |
| McGowan, I | 1 |
| Behrens, G; Bosse, M; Chuck, SK; Cohen, C; DeMorin, J; Elion, RA; Mills, A; Nelson, M; Orkin, C; Rijnders, B; Rimsky, L; Stevens, M; Thorpe, D; Vanveggel, S; White, K; Zhong, L | 1 |
| Hsiao, CB; Ma, Q; Sawyer, JR | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Rijnders, BJ; Rokx, C; Verbon, A | 1 |
| Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V | 1 |
| Amiel, C; Chas, J; Guessant, S; Hamidi, M; Kherallah, K; Lebrette, MG; Lependeven, C; Pialoux, G; Schneider, V | 1 |
| Baldeyrou, M; Batard, ML; Bernard-Henry, C; Cheneau, C; de Mautort, E; Fafi-Kremer, S; Gantner, P; Muret, P; Partisani, M; Priester, M; Reinhart, S; Rey, D | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Bastard, JP; Dubourg, O; Harent, S; Lariven, S; Lescure, FX; Nguyen, LB; Peytavin, G; Visseaux, B; Yazdanpanah, Y | 1 |
| Boyd, A; Fonquernie, L; Girard, PM; Meynard, JL; Morand-Joubert, L; Surgers, L; Valin, N; Viala, C | 1 |
| Deeks, ED | 1 |
| Back, DJ; Byakika-Kibwika, P; Else, L; Katwere, M; Khoo, SH; Lamorde, M; Merry, C; Mukisa, L; Sempa, JB; Walimbwa, S | 1 |
| Antinori, A; Brunetta, J; De-Oertel, S; Ebrahimi, R; Johnson, B; Johnson, M; Moreno Guillén, S; Shalit, P; Wade, B; Walker, I; Yeni, P | 1 |
| Amara, A; Back, D; Boffito, M; Dickinson, L; Else, L; Higgs, C; Jackson, A; Karolia, Z; Khoo, S; Moyle, G; Yapa, HM | 1 |
| Charpentier, C; Descamps, D; Joly, V; Landman, R; Lariven, S; Lê, MP; Peytavin, G; Phung, B; Visseaux, B; Yazdanpanah, Y; Yéni, P | 1 |
| Bossolasco, S; Castagna, A; Cernuschi, M; Cinque, P; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Nozza, S; Poli, A; Spagnuolo, V; Tambussi, G | 1 |
| Calvez, V; Marcelin, AG; Meynard, JL; Morand-Joubert, L; Surgers, L; Todesco, E | 1 |
| Awni, W; Dunbar, M; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R | 1 |
| Carrero, A; Collado, A; de Lagarde-Sebastián, M; Delgado-Fernández, M; Espinosa, N; Gómez-Berrocal, A; Hernández-Quero, J; Hontañón-Antoñana, V; Jiménez-Aguilar, P; Macías, J; Merino, D; Neukam, K; Pérez-Camacho, I; Pineda, JA; Ríos, MJ; Rivero-Juárez, A; Ruiz-Morales, J; Téllez, F; Vera-Méndez, F | 1 |
| Allavena, C; Andre, E; Calvez, V; Flandre, P; Grude, M; Jovelin, T; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Raffi, F; Rodallec, A; Sayon, S; Wirden, M | 1 |
| Atta, MG; Decker, BS; Gupta, SK; Kashuba, ADM; Slaven, JE; Wyatt, CM | 1 |
| Destache, CJ; Mandal, S; Prathipati, PK | 1 |
| Ammassari, A; Andreoni, M; Antinori, A; Armenia, D; Bellagamba, R; Berno, G; Bertoli, A; Bonora, S; Calcagno, A; Carta, S; Ceccherini-Silberstein, F; Cicalini, S; Continenza, F; Di Carlo, D; Di Perri, G; Fedele, V; Forbici, F; Ghisetti, V; Libertone, R; Perno, CF; Santoro, MM; Vendemiati, G; Zaccarelli, M | 1 |
| Ahmad, S; Brima, N; Chaponda, M; Davies, C; Hay, P; Johnson, M; Kingston, M; Lewis, JM; Marshall, N; Mulka, L; Muqbill, G; Nelson, M; Shaw, J; Smith, C; Tomkins, A; Torkington, A; Waters, L; Williams, D | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Liu, Y; Martorell, CT; Mills, A; Molina, JM; Porter, D; Post, FA; Quirk, E; Ramgopal, M; Ruane, P; SenGupta, D; Stellbrink, HJ; Valero, IP | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Lazzarin, A; Liu, HC; Mills, A; Orkin, C; Podzamczer, D; Porter, D; Quirk, E; Ramgopal, M; Rijnders, B; Rockstroh, J; Ruane, P; SenGupta, D; Stoeckle, M; Thalme, A; Vandercam, B | 1 |
| Battegay, M; Bernasconi, E; Calmy, A; Cavassini, M; Fehr, J; Gayet-Ageron, A; Hirzel, C; Schmid, P; Sculier, D | 1 |
| Arrabal-Durán, P; Chamorro-de-Vega, E; Gijón-Vidaurreta, P; Herranz-Alonso, A; Rodríguez-González, CG; Sanjurjo-Sáez, M | 1 |
| Shafer, RW | 1 |
| Carbone, A; Castagna, A; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Spagnuolo, V | 1 |
| Caglayan, MG; Gumustas, M; Onur, F; Ozkan, SA | 1 |
| Aboud, M; Angelis, K; Cupo, M; De Wet, J; Gartland, M; Kahl, LP; Lupo, S; McComsey, GA; Parks, D; Poggio, MC; Vandermeulen, K; Wynne, B | 1 |
| Aboud, M; Angelis, K; Blair, EA; Brinson, C; Castelli, F; Gartland, M; Girard, PM; Hung, CC; Kahl, LP; Llibre, JM; Smith, K; Underwood, M; Vandermeulen, K; Wynne, B | 1 |
| Eron, JJ; Hoffman, E; Hudgens, M; Marcus, C; Menezes, P; Mollan, K; Rublein, J; Wills, J; Xie, Z | 1 |
| Casado, JL; Fontecha, M; Monsalvo, M; Rodriguez-Sagrado, MA; Rojo, AM | 1 |
| Bachiller, P; Bahamonde, A; Barberá, JR; Casado, A; Diz, J; Domingo, P; Fernández, P; Lorenzo, JF; Martínez, E; Mayorga, MI; Muñoz, A; Ocampo, A; Podzamczer, D; Rodriguez, M; Rozas, N; Salgado, X; Santos, J; Sepúlveda, MA; Torres, C; Yzusqui, M | 1 |
| Bauer, U; Bobardt, J; Iakoubov, R; Schmid, RM; Schneider, J; Schulz, S; Spinner, CD; Von Werder, A; Wolf, E; Zink, A | 1 |
| Allavena, C; Billaud, E; Bonnet, B; Bouchez, S; Chauveau, M; Hall, N; Hitoto, H; Merrien, D; Michau, C; Perez, L; Raffi, F; Sécher, S | 1 |
| Boyer, EW; Carrico, AW; Chai, PR; Jambaulikar, GD; Mayer, KH; O'Cleirigh, C; Pereira, LM | 1 |
| Gatanaga, H; Oka, S | 1 |
| Allavena, C; Chauveau, M; Raffi, F | 1 |
| Bai, F; Bandera, A; Bernasconi, DP; Bonora, S; Castelli, F; Di Biagio, A; Focà, E; Gori, A; Lapadula, G; Migliorino, GM; Monforte, AD; Squillace, N | 1 |
| Briano, F; Comi, L; Di Biagio, A; Di Filippo, E; Giacomini, M; Gori, A; Maggiolo, F; Mora, S; Riccardi, N; Taramasso, L | 1 |
| Berruti, M; Briano, F; Di Biagio, A; Taramasso, L | 1 |
| Bouazza, N; Bregigeon, S; Descamps, D; Dhiver, C; Gattacceca, F; Lacarelle, B; Lê, MP; Mokhtari, S; Néant, N; Peytavin, G; Solas, C; Tamalet, C; Yazdanpanah, Y | 1 |
| Bermejo-Vicedo, T; Gramage-Caro, T; Montero-Llorente, B; Rodríguez-Sagrado, MÁ; Vélez-Díaz-Pallarés, M | 1 |
| Alagaratnam, J; Boffito, M; Bozzali, M; Cercignani, M; Mora-Peris, B; Nelson, M; Toniolo, S; Underwood, J; Vera, JH; Winston, A | 1 |
| Bassetti, M; Beltramini, S; Briano, F; Bruno, SR; Di Biagio, A; Ferrara, S; Giacomini, M; Lo Caputo, S; Magnasco, L; Mora, S; Pincino, R; Poliseno, M; Sarteschi, G; Sasso, E; Taramasso, L | 1 |
| Bernardino, JI; de Gea Grela, A; Martín Carbonero, L; Micán, R; Ramos, L; Valencia, ME | 1 |
| Derkach, EV; Pyadushkina, EA | 1 |
| Berni, A; Castagna, A; Cazanave, C; Chounta, V; D'Amico, R; Di Perri, G; Diaz-Brito, V; Dretler, R; Garges, HP; Latham, CL; Oka, S; Osiyemi, O; Pascual Bernáldez, M; Patel, P; Ramgopal, MN; Sims, J; Smith, K; Spreen, WR; Sutherland-Phillips, D; Sutton, K; Van Eygen, V; Van Solingen-Ristea, R; van Wyk, J; Walmsley, S; Zhang, F | 1 |
7 review(s) available for tenofovir and rilpivirine
| Article | Year |
|---|---|
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Oxazines; Pyrimidines; Rilpivirine; Tenofovir | 2012 |
Single-tablet regimens in HIV: does it really make a difference?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tablets; Tenofovir; Thiazoles | 2014 |
[Mechanism of action and pharmacokinetics of rilpivirine].
Topics: Adenine; Adult; Aged; Animals; Anti-HIV Agents; Biological Availability; Child; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Administration Routes; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Food-Drug Interactions; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Intestinal Absorption; Molecular Structure; Nanoparticles; Nitriles; Organophosphonates; Proton Pump Inhibitors; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir | 2013 |
An overview of antiretroviral pre-exposure prophylaxis of HIV infection.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Maraviroc; Medication Adherence; Nitriles; Organophosphonates; Pre-Exposure Prophylaxis; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Triazoles | 2014 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tablets; Tenofovir | 2014 |
Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection.
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine; Tenofovir | 2018 |
16 trial(s) available for tenofovir and rilpivirine
| Article | Year |
|---|---|
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutation; Nitriles; Nucleosides; Nucleotides; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutation; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black or African American; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sex Factors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Topics: Adenine; Adult; Anti-HIV Agents; Cross-Over Studies; Deoxycytidine; Drug Combinations; Emtricitabine; Fasting; Female; Food-Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tablets; Tenofovir; Young Adult | 2014 |
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Patient Outcome Assessment; Patient Satisfaction; Rilpivirine; Tenofovir | 2015 |
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Emtricitabine; Female; HIV Infections; Humans; Middle Aged; Organophosphates; Rilpivirine; Tenofovir; Young Adult | 2015 |
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Osteoporosis; Oxazines; Pelvic Bones; Piperazines; Pyridones; Rilpivirine; Spine; Tenofovir; Treatment Outcome | 2018 |
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.
Topics: Adult; Aged; Anti-HIV Agents; Bone Density; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Effects of antiretroviral combination therapies F/TAF, E/C/F/TAF and R/F/TAF on insulin resistance in healthy volunteers: the TAF-IR Study.
Topics: Adenine; Adult; Anti-HIV Agents; Blood Glucose; Body Weight; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Glucose Clamp Technique; Healthy Volunteers; Humans; Insulin Resistance; Male; Prospective Studies; Rilpivirine; Tenofovir | 2018 |
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition; Cyclopropanes; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Quality of Life; Rilpivirine; RNA, Viral; Sleep; Tenofovir; Viral Load | 2020 |
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a random
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Female; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Injection Site Reaction; Male; Middle Aged; Rilpivirine; RNA; Tenofovir; Viral Load; Young Adult | 2023 |
46 other study(ies) available for tenofovir and rilpivirine
| Article | Year |
|---|---|
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship | 2009 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; Congresses as Topic; Darunavir; Drugs, Investigational; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Peptide Fragments; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Rilpivirine; Societies, Scientific; Sulfonamides; Tenofovir; Zalcitabine | 2005 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load | 2011 |
FDA notifications. Complera approved.
Topics: Adenine; Deoxycytidine; Drug Approval; Drug Combinations; Drug Labeling; Emtricitabine; HIV Infections; Humans; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; United States; United States Food and Drug Administration | 2011 |
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.
Topics: Adenine; Anti-HIV Agents; APOBEC Deaminases; Cytidine Deaminase; Cytosine Deaminase; DNA Mutational Analysis; Drug Resistance, Viral; Female; Glutamic Acid; HIV Reverse Transcriptase; HIV-1; Humans; Isoleucine; Lysine; Male; Methionine; Mutation; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Rilpivirine; Tenofovir; Treatment Failure; Virus Replication | 2012 |
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Patient Compliance; Pyrimidines; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Organophosphonates; Prevalence; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir | 2013 |
Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Synergism; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcription; Rilpivirine; Tenofovir; Virus Cultivation | 2014 |
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2014 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles | 2014 |
Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Nitriles; Organophosphonates; Pilot Projects; Prospective Studies; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load; Young Adult | 2014 |
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Nitriles; Organophosphonates; Prospective Studies; Pyrimidines; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir | 2014 |
Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cohort Studies; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Skeletal muscle toxicity associated with emtricitabine/rilpivirine/tenofovir fixed-dose combination: a case report.
Topics: Adenine; Deoxycytidine; Drug Combinations; Emtricitabine; Histocytochemistry; Humans; Lipodystrophy; Male; Microscopy; Middle Aged; Muscle, Skeletal; Muscular Atrophy, Spinal; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir | 2014 |
Evaluation of the efficacy and safety of switching to tenofovir, emtricitabine, and rilpivirine in treatment-experienced patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Rilpivirine; Tenofovir; Young Adult | 2015 |
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Diet; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Middle Aged; Plasma; Rilpivirine; Tenofovir; Uganda; Young Adult | 2015 |
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Rilpivirine; Tenofovir; Viral Load | 2015 |
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir | 2015 |
Presence of Minority Resistant Variants After Failure of a Tenofovir, Emtricitabine, and Rilpivirine Regimen.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Rilpivirine; RNA-Directed DNA Polymerase; Tenofovir; Viral Load | 2016 |
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.
Topics: Alkynes; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Emtricitabine; Hepacivirus; HIV-1; Humans; Raltegravir Potassium; Rilpivirine; Tenofovir | 2016 |
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
Topics: Adult; Anti-Retroviral Agents; Antiviral Agents; Bilirubin; Case-Control Studies; Coinfection; Drug Therapy, Combination; Emtricitabine; Female; Fibrosis; Hepacivirus; Hepatitis C; HIV Infections; Hospitalization; Humans; Liver; Male; Middle Aged; Retrospective Studies; Rilpivirine; Spain; Tablets; Tenofovir; Transaminases | 2016 |
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Genotype; Genotyping Techniques; HIV Infections; Humans; Microbial Sensitivity Tests; Mutation; Proviruses; Rilpivirine; RNA, Viral; Tenofovir | 2016 |
Plasma and Intracellular Concentrations in HIV-Infected Patients Requiring Hemodialysis Dosed With Tenofovir Disoproxil Fumarate and Emtricitabine.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Prospective Studies; Renal Dialysis; Rilpivirine; RNA, Viral; Tenofovir; Young Adult | 2016 |
Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Topics: Animals; Anti-Retroviral Agents; Chromatography, Liquid; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Mice; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; Solid Phase Extraction; Tandem Mass Spectrometry; Tenofovir | 2016 |
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Topics: Adult; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Tablets; Tenofovir; Viral Load | 2017 |
Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; United Kingdom; Viral Load | 2017 |
Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
Topics: Adult; Anti-HIV Agents; Cholesterol, HDL; Drug Combinations; Drug Substitution; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Rilpivirine; RNA, Viral; Sustained Virologic Response; Tablets; Tenofovir; Triglycerides; Viral Load | 2017 |
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Lopinavir; Mutation; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Tenofovir | 2017 |
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Topics: Adult; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Rilpivirine; Tenofovir; Treatment Outcome | 2017 |
Simultaneous determination and validation of emtricitabine, rilpivirine and tenofovir from biological samples using LC and CE methods.
Topics: Anti-Retroviral Agents; Chromatography, Liquid; Electrophoresis, Capillary; Emtricitabine; Humans; Limit of Detection; Linear Models; Models, Statistical; Reproducibility of Results; Rilpivirine; Tenofovir | 2018 |
Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Emtricitabine; Energy Intake; Female; HIV Infections; Humans; Maintenance Chemotherapy; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Substitution; Dyslipidemias; Emtricitabine; Female; HIV Infections; Humans; Lipids; Male; Prospective Studies; Rilpivirine; Tenofovir; Viral Load | 2018 |
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Prospective Studies; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Short Communication: Bioequivalence of Tenofovir Component of Tenofovir/Rilpivirine/Emtricitabine in Digital Pills.
Topics: Adult; Anti-HIV Agents; Capsules; Drug Delivery Systems; Emtricitabine; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Female; Healthy Volunteers; HIV Infections; Humans; Male; Medication Adherence; Radio Waves; Rilpivirine; Tenofovir; Therapeutic Equivalency; United States; United States Food and Drug Administration | 2019 |
Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Prospective Studies; Rilpivirine; Tenofovir | 2019 |
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study-authors' response.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Prospective Studies; Rilpivirine; Tenofovir | 2019 |
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
Topics: Adenine; Adult; Anti-HIV Agents; Cholesterol; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lipid Metabolism; Lipidomics; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2019 |
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Female; Fumarates; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Weight Gain | 2020 |
Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Cohort Studies; Drug Monitoring; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; Viral Load; Young Adult | 2020 |
Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine
Topics: Adenine; Adult; Alanine; Antiviral Agents; Drug Combinations; Drug Substitution; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Prospective Studies; Rilpivirine; Tenofovir | 2020 |
Changes in functional connectivity in people with HIV switching antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asymptomatic Diseases; Benzoxazines; Cognitive Dysfunction; Connectome; Cyclopropanes; Drug Substitution; Emtricitabine; Executive Function; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxazines; Piperazines; Prospective Studies; Pyridones; Raltegravir Potassium; Rilpivirine; Tenofovir | 2020 |
Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
Topics: Anti-HIV Agents; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Retrospective Studies; Rilpivirine; Tablets; Tenofovir | 2022 |
[Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine].
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Tenofovir | 2022 |
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation].
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Rilpivirine; Tenofovir | 2021 |